Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28407999 | 0.82 | TSHR (0.43) | TSHR | |
| SCHEMBL14764019 | 0.70 | — | — | |
| SCHEMBL15786467 | 0.70 | — | — | |
| SCHEMBL6407067 | 0.70 | — | — | |
| SCHEMBL2721371 | 0.70 | — | — | |
| SCHEMBL2116254 | 0.69 | — | — | |
| SCHEMBL23607914 | 0.69 | MAPK1 (0.35) | TSHR | |
| SCHEMBL3378770 | 0.69 | — | — | |
| SCHEMBL270962 | 0.69 | — | — | |
| SCHEMBL10026572 | 0.69 | MEN1 (0.33) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090124819-A1 | 2-SUBSTITUTED VITAMIN D DERIVATIVES | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2009-05-14 | — | — | US | disclosed |
| EP-1466900-B1 | 2-SUBSTITUTED VITAMIN D DERIVATIVES | TAKAYAMA HIROAKI (JP) | 2009-01-14 | — | — | EP | disclosed |
| US-7402688-B2 | 2,2-Di-substituted 1alpha,25-dihydroxy-19-norvitamin D derivative | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2008-07-22 | — | — | US | disclosed |
| US-20060160779-A1 | 2,2-Di-substituted 1alpha,25-dihydroxy-19-norvitamin d derivative | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2006-07-20 | — | — | US | disclosed |
| US-20060074255-A1 | 3-Methyl-20-epi-vitamin D derivatives | TAKAYAMA HIROAKI | 2006-04-06 | — | — | US | disclosed |
| EP-1559708-A1 | 2,2-DI-SUBSTITUTED 1a,25-DIHYDROXY-19-NORVITAMIN D DERIVATIVE | Shimizu, Masato (JP) | 2005-08-03 | — | — | EP | disclosed |
| US-20050131242-A1 | 2-substituted vitamin d derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2005-06-16 | — | — | US | disclosed |
| US-20050119240-A1 | 1-methyl-20-epi-vitamin d derivative | CHUGAI SEIYAKU KAABUSHIKI KAISHA (JP) | 2005-06-02 | — | — | US | disclosed |
| US-20050032754-A1 | 5,6-Trans-2-alkylvitamin D derivatives | HIROAKI TAKAYAMA | 2005-02-10 | — | — | US | disclosed |
| EP-1466900-A1 | 2-SUBSTITUTED VITAMIN D DERIVATIVES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-10-13 | — | — | EP | disclosed |
| US-20040030167-A1 | 3-Methyl-20-epi-vitamin d derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-02-12 | — | — | US | disclosed |
| US-20030092687-A1 | 5,6-Trans-2-alkylvitamin d derivatives | HIROAKI TAKAYAMA (JP) | 2003-05-15 | — | — | US | disclosed |
| EP-1310484-A1 | 1-METHYL-20-EPIVITAMIN D DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-05-14 | — | — | EP | disclosed |
| EP-1284259-A1 | 5,6- i TRANS /i -2-ALKYLVITAMIN D DERIVATIVES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-02-19 | — | — | EP | disclosed |
| CN-1398254-A | Vitamin D derivatives having substituents at 2 alpha position | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2003-02-19 | — | — | CN | disclosed |
| US-20030022872-A1 | Vitamin d derivatives having substituents at the 2 alpha-position | TAKAYAMA, HIROAKI (JP) | 2003-01-30 | — | — | US | disclosed |
| EP-1260502-A1 | VITAMIN D DERIVATIVES HAVING SUBSTITUENTS AT THE 2ALPHA-POSITION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-11-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092687-A1 | 5,6-Trans-2-alkylvitamin d derivatives | VDR, CYP24A1, CYP2R1 | TSHR 190/4885 |
| US-20090124819-A1 | 2-SUBSTITUTED VITAMIN D DERIVATIVES | VDR, CYP2R1, CYP24A1 | TSHR 381/4885 |
| US-20040030167-A1 | 3-Methyl-20-epi-vitamin d derivatives | VDR, CYP24A1, CYP2R1 | TSHR 882/4885 |
| US-20050032754-A1 | 5,6-Trans-2-alkylvitamin D derivatives | VDR, CYP2R1, CYP24A1 | TSHR 155/4885 |
| US-20060160779-A1 | 2,2-Di-substituted 1alpha,25-dihydroxy-19-norvitamin d derivative | CYP24A1, CYP2R1, VDR | TSHR 575/4885 |
| US-20050131242-A1 | 2-substituted vitamin d derivatives | VDR, CYP2R1, CYP24A1 | TSHR 328/4885 |
| US-20060074255-A1 | 3-Methyl-20-epi-vitamin D derivatives | VDR, CYP2R1, CYP24A1 | TSHR 844/4885 |
| US-20030022872-A1 | Vitamin d derivatives having substituents at the 2 alpha-position | VDR, CYP24A1, CYP2R1 | TSHR 629/4885 |
| US-20050119240-A1 | 1-methyl-20-epi-vitamin d derivative | CYP24A1, VDR, CYP2R1 | TSHR 1177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.